In AML, inhibition of CD39 combined with TIGIT can increase AML cell lysis in 2/3 cell lines, and the combined inhibition of TIGIT and CD39 significantly improved NK cell killing activity in vitro, thus further enhancing the NK cell killing effect on AML cells (41, 42, 63). The gene discussed is TIGIT; the disease is acute myeloid leukemia.